215 related articles for article (PubMed ID: 23153310)
1. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
Kunavisarut T; Kak I; Macmillan C; Ralhan R; Walfish PG
BMC Cancer; 2012 Nov; 12():523. PubMed ID: 23153310
[TBL] [Abstract][Full Text] [Related]
2. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
3. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.
Ralhan R; Cao J; Lim T; Macmillan C; Freeman JL; Walfish PG
BMC Cancer; 2010 Jun; 10():331. PubMed ID: 20579375
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.
Ralhan R; He HC; So AK; Tripathi SC; Kumar M; Hasan MR; Kaur J; Kashat L; MacMillan C; Chauhan SS; Freeman JL; Walfish PG
PLoS One; 2010 Nov; 5(11):e14130. PubMed ID: 21152431
[TBL] [Abstract][Full Text] [Related]
5. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.
Srivastava G; Assi J; Kashat L; Matta A; Chang M; Walfish PG; Ralhan R
BMC Cancer; 2014 Sep; 14():726. PubMed ID: 25265904
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
Assi J; Srivastava G; Matta A; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2015; 10(2):e0107586. PubMed ID: 25695234
[TBL] [Abstract][Full Text] [Related]
8. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G
Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877
[TBL] [Abstract][Full Text] [Related]
9. [Expression of EpCAM and E-cadherin in papillary thyroid carcinoma and its clinicopathologic significance].
Cheng Y; Meng Y; Liang Z; Yang C; Luo Y; Cui Q
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):189-94. PubMed ID: 26268754
[TBL] [Abstract][Full Text] [Related]
10. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma.
Zhang Y; Pan J; Xu D; Yang Z; Sun J; Sun L; Wu Y; Qiao H
Oncol Rep; 2018 Dec; 40(6):3611-3624. PubMed ID: 30542708
[TBL] [Abstract][Full Text] [Related]
11. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance.
Zhou Y; Jiang HG; Lu N; Lu BH; Chen ZH
Asian Pac J Cancer Prev; 2015; 16(4):1605-8. PubMed ID: 25743839
[TBL] [Abstract][Full Text] [Related]
12. Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.
Somasundaram RT; Kaur J; Leong I; MacMillan C; Witterick IJ; Walfish PG; Ralhan R
BMC Cancer; 2016 Jul; 16():486. PubMed ID: 27421772
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
15. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors of Metastatic Lymph Nodes in Papillary Thyroid Microcarcinoma.
Ruiz Pardo J; Ríos A; Rodríguez JM; Paredes M; Soriano V; Oviedo MI; Hernández AM; Parrilla P
Cir Esp (Engl Ed); 2020 Apr; 98(4):219-225. PubMed ID: 31980154
[TBL] [Abstract][Full Text] [Related]
17. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?
Arora N; Turbendian HK; Kato MA; Moo TA; Zarnegar R; Fahey TJ
Thyroid; 2009 May; 19(5):473-7. PubMed ID: 19348582
[TBL] [Abstract][Full Text] [Related]
18. Which papillary thyroid microcarcinoma should be treated as "true cancer" and which as "precancer"?
Kaliszewski K; Diakowska D; Wojtczak B; Forkasiewicz Z; Pupka D; Nowak Ł; Rudnicki J
World J Surg Oncol; 2019 May; 17(1):91. PubMed ID: 31146753
[TBL] [Abstract][Full Text] [Related]
19. Management of cN0 papillary thyroid microcarcinoma patients according to risk-scoring model for central lymph node metastasis and predictors of recurrence.
Feng JW; Ye J; Wu WX; Qu Z; Qin AC; Jiang Y
J Endocrinol Invest; 2020 Dec; 43(12):1807-1817. PubMed ID: 32557354
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
